RxDoctor Payments Data

William Johnson, PA

Physician Assistant · Richmond, INNPI 1821570987

Payments from drug & device makers

$4,971in general payments, 2019–2025

Across 311 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$768
  • Amgen$700
  • Novartis$573
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$508
  • E.r. Squibb & Sons, L.L.C.$499
  • Boehringer Ingelheim$368
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,971100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,971 in reported general payments places this provider in the 90th percentile of 1,955 physician assistant providers in Indiana.

See all physician assistant providers in Indiana

Medicare billing

Part B allowed, 2024
$79,041
Medicare patients
590
Services billed
1,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban275$216,096
EntrestoSacubitril/Valsartan72$66,739
XareltoRivaroxaban55$46,040
JardianceEmpagliflozin55$39,886
FarxigaDapagliflozin Propanediol32$23,902
BrilintaTicagrelor27$14,030
Repatha PushtronexEvolocumab13$7,718
Ranolazine ErRanolazine39$5,350
Prasugrel Hcl21$3,709
Metoprolol Succinate249$2,462
Atorvastatin Calcium288$1,777
Amiodarone Hcl33$1,706
ClopidogrelClopidogrel Bisulfate162$1,334
Losartan Potassium168$1,275
Isosorbide Mononitrate ErIsosorbide Mononitrate159$1,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$216,096275 claims
NovartisEntresto$573$66,73972 claims
Johnson & JohnsonXarelto$768$46,04055 claims
Boehringer IngelheimJardiance$368$39,88655 claims
AstraZenecaFarxiga, Brilinta$127$37,93259 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,955 physician assistant providers in Indiana.

Other physician assistant in Richmond

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →